Airway Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
4
Active:2
Completed:1
Trial Phases
2 Phases
Phase 1:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Not Applicable
1 (25.0%)Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
Not Applicable
Active, not recruiting
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Other: Air-sham
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Airway Therapeutics, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT06897839
- Locations
- 🇮🇱
Bnai Zion Medical Center, Haifa, Israel
🇮🇱Shaare-Zedek Medical Center, Jerusalem, Israel
🇮🇱Ziv Medical Center, Safed, Israel
A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)
Phase 1
Completed
- Conditions
- Bronchopulmonary Dysplasia
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Airway Therapeutics, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT04662151
- Locations
- 🇪🇸
Airway Therapeutics Investigational Site, Málaga, Spain
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
Phase 1
Terminated
- Conditions
- UndefinedCOVID-19
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Airway Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04659122
- Locations
- 🇺🇸
Airway Therapeutics Investigational Site, Cincinnati, Ohio, United States
News
No news found